23andMe Regains Compliance With Nasdaq Listing Requirements
30 oct. 2024 17h00 HE
|
23andMe, Inc.
SUNNYVALE, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), a leading human genetics and preventive health company, today announced that the...
23andMe Appoints Three New Independent Directors to Board
29 oct. 2024 07h30 HE
|
23andMe, Inc.
SUNNYVALE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), a leading human genetics and preventive health company, today announced the...
23andMe Introduces New Feature Helping African Americans Trace Their Roots to Post Slavery Communities in the South
17 oct. 2024 16h05 HE
|
23andMe, Inc.
SUNNYVALE, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company, released a powerful new feature that enables African American customers to...
23andMe Announces Completion of 1-for-20 Reverse Stock Split
16 oct. 2024 08h15 HE
|
23andMe, Inc.
SUNNYVALE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), announced today the completion of the previously announced 1-for-20 reverse stock...
23andMe Announces 1-for-20 Reverse Stock Split
11 oct. 2024 08h15 HE
|
23andMe, Inc.
SUNNYVALE, Calif., Oct. 11, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), announced today that the 1-for-20 reverse stock split of the Company’s Class A and...
23andMe Announces Mathew Knowles as New Brand Ambassador
08 oct. 2024 07h00 HE
|
23andMe, Inc.
SUNNYVALE, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co., (Nasdaq: ME), a leading human genetics and preventive health company, today announced an ongoing collaboration with Mathew...
23andMe Launches New Genetic Report on Likelihood of Frequent Emotional Eating
25 sept. 2024 07h30 HE
|
23andMe, Inc.
SUNNYVALE, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co., (Nasdaq: ME), a leading human genetics and preventive health company, today released a new report on the genetics of...
Independent Directors of 23andMe Resign from Board
17 sept. 2024 16h26 HE
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2024 (GLOBE NEWSWIRE) -- The independent directors of the Board of 23andMe Holding Co. (Nasdaq: ME), today sent the following letter to Anne Wojcicki, Chief...
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
15 sept. 2024 03h00 HE
|
23andMe, Inc.
23ME-01473 inhibited tumor growth in a patient-derived xenograft mouse model of non-small cell lung cancer Elevated levels of soluble and tumor-bound ULBP6 confirmed in squamous cell carcinomas and...
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
15 sept. 2024 03h00 HE
|
23andMe, Inc.
23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one confirmed partial response Higher tumor expression of CD200 and human...